Ovid

News

Are biotech IPOs back in fashion?

After a slow first quarter, biotech IPOs may finally start to come into vogue in the coming months as a series of companies announced plans to go public.

News

Takeda to challenge GW Pharma with epilepsy deal

Takeda makes epilepsy deal as GW prepares for US filing.

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks